SCHEMBL1770011

SCHEMBL1770011

CCC(=NNC(=N)N)C(C)=NNC(=N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770152 0.87
SCHEMBL1770184 0.79 PLK4 (0.35)
SCHEMBL27111321 0.79 PLK4 (0.35)
SCHEMBL7861521 0.78 HIF1A (0.34)
SCHEMBL7859383 0.78 HIF1A (0.34)
SCHEMBL7859385 0.78 HIF1A (0.34)
SCHEMBL11673290 0.76
SCHEMBL18725175 0.76
SCHEMBL16275210 0.76
Hydrochloric Acid SCHEMBL9710685 0.74 PLK4 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3831372-A1 MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS Pathologica LLC (US) 2021-06-09 EP disclosed
US-20210085625-A1 CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG PATHOLOGICA LLC 2021-03-25 US disclosed
US-10881626-B2 Controlled release oral pharmaceutical dosage forms comprising MGBG PATHOLOGICA LLC (US) 2021-01-05 US disclosed
US-20190224144-A1 METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING PATHOLOGICA LLC 2019-07-25 US disclosed
US-10350178-B2 Methods and compositions for treatment of demyelinating diseases PATHOLOGICA LLC (US) 2019-07-16 US disclosed
US-10292950-B2 Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing PATHOLOGICA LLC (US) 2019-05-21 US disclosed
EP-3473247-A1 COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS Pathologica LLC (US) 2019-04-24 EP disclosed
US-20180369170-A1 METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING PATHOLOGICA LLC 2018-12-27 US disclosed
US-20180360783-A1 METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES PATHOLOGICA LLC 2018-12-20 US disclosed
EP-2453886-B1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2018-12-12 EP disclosed
US-20140187643-A1 Method of Treatment with Anti-Inflammatory and Analgesic Compounds Which are GI-, Renal-, and Platelet-Sparing PATHOLOGICA LLC (US) 2014-07-03 US disclosed
US-20140051765-A1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2014-02-20 US disclosed
US-8609734-B2 Methods of treating pain with MGBG Pathdogica, LLC (US) 2013-12-17 US disclosed
US-20130317113-A1 REGULATION OF OSTEOPONTIN PATHOLOGICA LLC (US) 2013-11-28 US disclosed
US-8445540-B2 Decreasing the activity of osteopontin in a cell comprising contacting the cell with an agent which inhibits S-adenosyl methionine decarboxylase, inhibits polyamine biosynthesis, or increases adenosine; MGBG, MDL73811, CGP48664, Berenil, Pentamidine, SL47, and/or SL93; autoimmune diseases; antitumor; HIV PATHOLOGICA LLC (US) 2013-05-21 US disclosed
US-20120289604-A1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2012-11-15 US disclosed
US-20120269891-A1 CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG PATHOLOGICA LLC (US) 2012-10-25 US disclosed
US-8258186-B2 Pharmaceutical for oral delivery comprising MGBG PATHOLOGICA, LLC (US) 2012-09-04 US disclosed
US-20110112199-A1 PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE PATHOLOGICA LLC (US) 2011-05-12 US disclosed
US-20080262092-A1 REGULATION OF OSTEOPONTIN PATHOLOGICA LLC. (US) 2008-10-23 US disclosed